Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups
Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL
New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers
2 Commerce Drive
Cranbury, NJ 08512